Overview
The Metabolic Bundle II: Synergy combines Tirzepatide and MOTS-c to support investigation into more complex metabolic signaling frameworks. In laboratory research settings, this pairing allows researchers to study how dual-incretin receptor engagement interacts with mitochondrial-derived peptide signaling within controlled metabolic models.
This bundle is supplied strictly for laboratory and investigational research purposes.
Compound Breakdown
Each peptide in the Metabolic Bundle II contributes a distinct but complementary metabolic signaling role:
Tirzepatide (15mg) — studied for its dual agonist activity at glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors
MOTS-c (10mg) — investigated as a mitochondrial-derived peptide involved in intracellular metabolic regulation and mitochondrial-nuclear communication
Together, these compounds allow researchers to examine coordinated incretin-based signaling alongside mitochondrial regulatory pathways.
Research Context
Research investigations involving the Metabolic Bundle II: Synergy commonly explore:
Dual-agonist incretin signaling models
Comparative studies versus GLP-1–only metabolic research compounds
Integrated mitochondrial and endocrine signaling frameworks
Progressive metabolic research designs beyond foundational pathway analysis
These investigations remain limited to controlled laboratory environments and do not imply clinical or therapeutic outcomes.
Related Categories
Researchers evaluating this bundle often review the individual components — Tirzepatide Peptide and MOTS-c Peptide — as well as adjacent formulations such as Metabolic Bundle I: Classic and Metabolic Bundle III: Next Gen.
